SCHEMBL4394336

SCHEMBL4394336

CC(C)(C)[Si](C)(C)OC1CCN(C(c2ccccc2)(c2ccccc2)c2ccccc2)CC1=CCN1CCCCC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 5/20 0.34
CHRM1 P11229 5/20 0.34
KCNH2 Q12809 4/20 0.34
HTR1A P08908 3/20 0.34
OPRM1 P35372 3/20 0.34
ADRA2A P08913 1/20 0.34
DRD1 P21728 1/20 0.34
TBXA2R P21731 1/20 0.34
ACHE P22303 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
ADRA1A P35348 1/20 0.34
DRD3 P35462 1/20 0.34
SLC6A3 Q01959 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
CYP2D6 P10635 4/20 0.33
CHRM3 P20309 4/20 0.33
CHRM4 P08173 2/20 0.33
CHRM5 P08912 2/20 0.33
GRIN2D O15399 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4394332 1.00 CHRM2 (0.34) CHRM2CHRM1KCNH2HTR1AOPRM1
SCHEMBL4394334 1.00 CHRM2 (0.34) CHRM2CHRM1KCNH2HTR1AOPRM1
SCHEMBL4391757 0.91 MEN1 (0.38) OPRM1TSHRLMNA
SCHEMBL4391761 0.91 MEN1 (0.38) OPRM1TSHRLMNA
SCHEMBL4391754 0.91 MEN1 (0.38) OPRM1TSHRLMNA
SCHEMBL4385191 0.90 CHRM3 (0.33) CHRM3
SCHEMBL4385194 0.90 CHRM3 (0.33) CHRM3
SCHEMBL4385196 0.90 CHRM3 (0.33) CHRM3
SCHEMBL3733534 0.86 CHRM3 (0.31) CHRM2CHRM3LMNA
SCHEMBL3741223 0.86 CHRM3 (0.31) CHRM2CHRM3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306059-A1 CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-12-10 US disclosed
EP-1889835-A1 CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP Daiichi Sankyo Company, Limited (JP) 2008-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306059-A1 CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP CBR3, CNR1, C3AR1 CHRM2 13/4885CHRM1 6/4885KCNH2 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.